Isoniazid (INH) is one of the most active compounds used to treat tuberculosis (TB)
worldwide. In addition, INH has been used as a prophylactic drug for individuals with latent …

Molecular diagnostics are revolutionising the clinical practice of infectious disease. Their
effects will be significant in acute-care settings where timely and accurate diagnostic tools …

La prueba molecular Genotype® MTBDRplus, es un método que permite identificar las
mutaciones más frecuentes asociadas con la resistencia a las drogas antituberculosas de …

Knowledge of the molecular genetic basis of resistance to antituberculous agents has
advanced rapidly since we reviewed this topic 3 years ago. Virtually all isolates resistant to …

ABSTRACT In total, 521 nonrespiratory specimens (91 urine, 30 gastric aspirate, 245 tissue,
113 pleural fluid, 19 cerebrospinal fluid [CSF], and 23 stool specimens) submitted to the …

The determination of antimicrobial susceptibility of a clinical isolate, especially with
increasing resistance, is often crucial for the optimal antimicrobial therapy of infected …

The genus Mycobacterium contains several slow-growing human pathogens, including
Mycobacterium tuberculosis, Mycobacterium leprae, and Mycobacterium avium …

Drug resistance in tuberculosis (TB) is a particular problem because the lengthy therapy of
at least 6 months makes patient compliance very difficult, which frequently creates drug …

The preferred antitubercular drug isoniazid specifically targets a long-chain enoyl-acyl
carrier protein reductase (InhA), an enzyme essential for mycolic acid biosynthesis in …

Abstract The diarylquinoline R207910 (TMC207) is a promising candidate in clinical
development for the treatment of tuberculosis. Though R207910-resistant mycobacteria bear …